Eisai (ESAIY) and Biogen (BIIB) announced that the Biologics License Application, BLA, for the subcutaneous formulation of “Leqembi,” an anti-amyloid beta protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration, NMPA, of China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $201 from $191 at Bernstein
- Biogen price target raised to $228 from $194 at H.C. Wainwright
- Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating
- Biogen price target raised to $200 from $190 at Wells Fargo
- Biogen price target raised to $207 from $189 at BofA